Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Staidson (Beijing) Biopharmaceuticals Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Staidson (Beijing) Biopharmaceuticals Co's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Staidson (Beijing) Biopharmaceuticals Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co LT-Debt-to-Total-Asset Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Staidson (Beijing) Biopharmaceuticals Co LT-Debt-to-Total-Asset Calculation

Staidson (Beijing) Biopharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.06	/	1149.608
	=	0.00

Staidson (Beijing) Biopharmaceuticals Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0.06	/	1149.608
	=	0.00

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Staidson (Beijing) Biopharmaceuticals Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Staidson (Beijing) Biopharmaceuticals Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176

Website

http://www.staidson.com

Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.

Executives

Zhang Hong Shan	Supervisors
Zheng Hong	Supervisors
Cheng Jiang Hong	Executives
Feng Yu Jing	Executives
Ma Li Na	Secretary, Director
Zhou Zhi Wen	Director
Wang Huan	Securities Affairs Representative
Zhang Rong Qin	Executives
Xu Jiang Ping	Executives
Cao Hai Yan	Supervisors
Sun Yan Fang	Executives
Jiang Li Xin	Director
Gu Jian Ping	Director
Xu Xiang Qing	Supervisors
Gu Zhen Qi	Director

Staidson (Beijing) Biopharmaceuticals Co Headlines

No Headlines